Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp |
Therapy | Eftilagimod alpha + Pembrolizumab |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | head and neck squamous cell carcinoma | predicted - sensitive | Eftilagimod alpha + Pembrolizumab | Phase II | Actionable | In a Phase II trial, Eftilagimod alpha (IMP321) and Keytruda (pembrolizumab) combination therapy resulted in an objective response rate (ORR) of 29.7% (11/37) and disease control rate (DCR) of 37.8% in patients with recurrent or metastatic head and neck squamous cell carcinoma, with an ORR of 60% (9/15), median progression-free survival of 13.6 months, and a median overall survival of 15.5 months in patients with high CD274 expression (PD-L1; CPS>/=20) (PMID: 38995265; NCT03625323). | 38995265 |
PubMed Id | Reference Title | Details |
---|---|---|
(38995265) | Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma. | Full reference... |